Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2016 - 2025)

Ironwood Pharmaceuticals' Cash & Equivalents history spans 17 years, with the latest figure at $215.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 143.29% year-over-year to $215.5 million; the TTM value through Dec 2025 reached $215.5 million, up 143.29%, while the annual FY2025 figure was $215.5 million, 143.29% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $215.5 million at Ironwood Pharmaceuticals, up from $140.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $740.3 million in Q1 2023 and bottomed at $88.2 million in Q3 2024.
  • The 5-year median for Cash & Equivalents is $195.4 million (2023), against an average of $326.6 million.
  • The largest annual shift saw Cash & Equivalents tumbled 85.96% in 2023 before it surged 143.29% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $620.1 million in 2021, then rose by 5.82% to $656.2 million in 2022, then crashed by 85.96% to $92.2 million in 2023, then decreased by 3.9% to $88.6 million in 2024, then soared by 143.29% to $215.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Cash & Equivalents are $215.5 million (Q4 2025), $140.4 million (Q3 2025), and $92.9 million (Q2 2025).